Education
About Us
Working with TipRanks
Follow Us
Kamada Ltd (IL:KMDA)
:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,745.08 - 2,960.32
Previous CloseN/A
Volume698.59K
Average Volume (3M)106.26K
Market Cap
1.46B
Enterprise Value1.03B
Total Cash (Recent Filing)$78.44M
Total Debt (Recent Filing)$11.06M
Price to Earnings (P/E)27.2
Beta0.59
Next Earnings
May 27, 2025EPS Estimate
25.19Last Dividend Ex-Date
Mar 17, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding57,505,030
10 Day Avg. Volume151,313
30 Day Avg. Volume106,258
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.66
Enterprise Value/Ebitda33.92
Forecast
1Y Price Target
4,815.56Price Target Upside89.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PositionWith a solid cash position and no long-term debt, Kamada is in a good financial position to acquire more products for its portfolio, potentially expanding growth.
Product Line ExpansionKamada has expanded its specialty plasma-derived product line through acquisitions and organic growth, which is expected to drive double-digit revenue growth and expanding margins.
R&D PipelineAn active internal R&D pipeline includes a novel AAT Deficiency treatment entering a Phase 3 trial, which could expand the treatment of this under-diagnosed genetic respiratory ailment.
Bears Say
AAT Trial EnrollmentEnrollment in the AAT trial is expected to be a challenge despite additional sites being opened.
Partnership ChallengesDespite prior positive guidance from the European Medicines Agency, Kamada has yet to find a partner for the AAT program.
---
KMDA FAQ
What was Kamada Ltd’s price range in the past 12 months?
Kamada Ltd lowest stock price was 1745.08 and its highest was 2960.32 in the past 12 months.
What is Kamada Ltd’s market cap?
Kamada Ltd’s market cap is 1.46B.
When is Kamada Ltd’s upcoming earnings report date?
Kamada Ltd’s upcoming earnings report date is May 27, 2025 which is in 57 days.
How were Kamada Ltd’s earnings last quarter?
Kamada Ltd released its earnings results on Mar 05, 2025. The company reported 26.835 earnings per share for the quarter, beating the consensus estimate of 19.483 by 7.352.
Is Kamada Ltd overvalued?
According to Wall Street analysts Kamada Ltd’s price is currently Undervalued.
Does Kamada Ltd pay dividends?
Kamada Ltd pays a Notavailable dividend of 72.1 which represents an annual dividend yield of N/A. See more information on Kamada Ltd dividends here
What is Kamada Ltd’s EPS estimate?
Kamada Ltd’s EPS estimate is 25.19.
How many shares outstanding does Kamada Ltd have?
Kamada Ltd has 57,505,030 shares outstanding.
What happened to Kamada Ltd’s price movement after its last earnings report?
Kamada Ltd reported an EPS of 26.835 in its last earnings report, beating expectations of 19.483. Following the earnings report the stock price went up 6.24%.
Which hedge fund is a major shareholder of Kamada Ltd?
Among the largest hedge funds holding Kamada Ltd’s share is ARK Investment Management LLC. It holds Kamada Ltd’s shares valued at 0.
---
Kamada Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
4,815.56 (89.81% Upside)
4,815.56 (89.81% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.78%
12-Months-Change
Fundamentals
Return on Equity
5.74%
Trailing 12-Months
Asset Growth
4.89%
Trailing 12-Months
Company Description
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
---
KMDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Kamada delivered strong financial performance in 2024 with record revenues and adjusted EBITDA, supported by successful product launches and expansion of plasma collection centers. However, increased operating expenses and financial challenges in Q4 2024 were noted. The company's positive outlook for 2025, including expected revenue and EBITDA growth, and the declaration of a special dividend, indicate confidence in future performance.Read More>---
KMDA Stock 12 Month Forecast
Average Price Target
4,815.56
▲(89.81% Upside)
Technical Analysis
Best Analysts Covering KMDA
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+12.26%
reiterated a buy rating 26 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +12.26% per trade.
---